Semaglutide Resistance: Why the Medicine Stops Working as Well

Step 1: Understand what 'resistance' actually means here

The word resistance carries heavy baggage. In common use it implies the medicine has become useless, which is rarely accurate. A more precise framing: semaglutide works by activating GLP-1 receptors in the gut, pancreas and brain, reducing appetite and slowing gastric emptying. Over weeks and months, a handful of things can reduce the functional effect of that activation without the receptors themselves failing.

First, as body weight falls, resting energy expenditure drops. A lighter body burns fewer calories at rest, so the same degree of appetite suppression produces a smaller calorie deficit than it did at the start. This is metabolic adaptation, not receptor-level resistance, and it is the reason nearly every weight-loss intervention produces a plateau eventually. The NHS medicines page for semaglutide notes that the medicine is prescribed alongside dietary changes and increased activity precisely because lifestyle factors continue to matter throughout treatment.

Second, there is emerging evidence that GLP-1 receptor expression and sensitivity may shift with prolonged agonist exposure, though this is better characterised in animal models than in human clinical data. Calling it classical resistance overstates what is currently known. What the data shows clearly is that weight loss curves for semaglutide typically plateau around 60–68 weeks, even at the full 2.4 mg maintenance dose used in the STEP 1 trial.

A common misconception worth naming gently: many people assume a plateau means the medicine has completely stopped working. Often it is still suppressing appetite and preserving weight that would otherwise have returned. Holding stable can itself be a meaningful clinical outcome.

Step 2: Map the likely contributors before concluding the medicine has failed

Before a prescriber considers switching treatment, they will usually work through a short checklist of modifiable factors. This is worth knowing because several of them are addressable without changing the medicine at all.

Dose adequacy is the first question. Semaglutide is titrated from 0.25 mg upward; people who plateau at an intermediate dose sometimes see renewed progress when titrated to 1.7 mg or 2.4 mg. If you are already on the 2.4 mg maintenance dose, this lever has been pulled. The MHRA has since approved a 7.2 mg semaglutide pen, though prescribing at that level follows specific clinical criteria and availability is confirmed at consultation.

Gut tolerance adaptations also matter. Early in treatment, slowed gastric emptying is very noticeable and powerfully reduces appetite. Over time the gut partially adapts, meaning meals clear more quickly and the fullness signal is less pronounced. This is physiological, not a failure of the medicine.

Lifestyle drift is the third contributor. The relationship between semaglutide and metabolic factors like insulin resistance means that eating patterns, sleep, and activity levels interact with how the medicine performs. A review of what has changed since treatment started is often more useful than an immediate prescription change.

Finally, medications added since starting semaglutide, or changes in thyroid function or other hormonal factors, can affect the treatment picture. Some people also notice unexpected physical symptoms during this period, and understanding why fainting can occur on Wegovy is one example of how side-effect awareness supports safer, more informed use. A prescriber reviewing the whole clinical context will spot these.

Step 3: Know what the evidence says about switching or escalating

When a genuine plateau has been confirmed and modifiable factors have been addressed, the clinical question becomes whether an alternative medicine might offer a different response. The strongest evidence here comes from the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, which compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks. Tirzepatide, a dual GIP and GLP-1 receptor agonist, produced greater average weight reduction. The dual-receptor mechanism means it activates a pathway semaglutide does not, which is the pharmacological basis for switching in cases of reduced semaglutide response.

NICE's appraisal of tirzepatide, TA1026, published in December 2024, recommends it for adults with a BMI of 35 or above alongside at least one weight-related condition, with lower BMI thresholds applying for some ethnic backgrounds. Whether a switch is clinically appropriate depends on the individual's full picture: current weight, comorbidities, which dose of semaglutide was reached, and contraindications.

It is also worth noting that stopping semaglutide without a plan typically leads to weight regain; the mechanism suppressing appetite is removed. Any transition should be managed by a prescriber, with a structured handover rather than an abrupt stop.

Step 4: Have the right conversation with your prescribing team

A plateau does not need to feel like a dead end. At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is dispensed, no automation, no rubber-stamping. That review is the right moment to raise a plateau, describe what has changed, and ask directly whether the current dose is still optimal or whether a clinical conversation about alternatives makes sense. Our clinical team reviews these questions regularly.

If you are comparing how semaglutide and tirzepatide perform side by side, the evidence on semaglutide and insulin resistance is a useful piece of the picture, as is the broader treatment landscape for weight management in the UK. For an overview of what access looks like in practice, the Wegovy assistance program page sets out what support is available for people who need help with access or cost alongside their treatment plan, and you can also find details of wegovy assistance options, including how to apply and what you may be eligible for.

If you would like a prescriber to review your current treatment, speak to our prescribers via a free consultation.